Voyager Therapeutics (VYGR) Total Current Liabilities (2016 - 2025)
Voyager Therapeutics (VYGR) has disclosed Total Current Liabilities for 11 consecutive years, with $26.5 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities fell 46.69% to $26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.5 million through Dec 2025, down 46.69% year-over-year, with the annual reading at $26.5 million for FY2025, 46.69% down from the prior year.
- Total Current Liabilities hit $26.5 million in Q4 2025 for Voyager Therapeutics, down from $35.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $101.7 million in Q1 2022 to a low of $19.9 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $50.8 million across 5 years, with a median of $44.8 million in 2023.
- Biggest five-year swings in Total Current Liabilities: surged 310.8% in 2022 and later plummeted 80.39% in 2023.
- Year by year, Total Current Liabilities stood at $51.0 million in 2021, then surged by 42.39% to $72.6 million in 2022, then dropped by 11.13% to $64.5 million in 2023, then fell by 22.82% to $49.8 million in 2024, then tumbled by 46.69% to $26.5 million in 2025.
- Business Quant data shows Total Current Liabilities for VYGR at $26.5 million in Q4 2025, $35.5 million in Q3 2025, and $42.0 million in Q2 2025.